Managing bone mineral density with oral bisphosphonate therapy in women with breast cancer receiving adjuvant aromatase inhibition

The use of adjuvant aromatase inhibitors is associated with an increased risk of osteoporosis and fractures. The oral bisphosphonate, risedronate - dosed as the US Food and Drug Administration approved for the treatment or prevention of postmenopausal osteoporosis - appears to mitigate bone loss ass...

Descripción completa

Detalles Bibliográficos
Autor principal: Van Poznak, Catherine
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2010
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917025/
https://www.ncbi.nlm.nih.gov/pubmed/20584345
http://dx.doi.org/10.1186/bcr2584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2917025/
https://www.ncbi.nlm.nih.gov/pubmed/20584345
http://dx.doi.org/10.1186/bcr2584

Ejemplares similares